Skip to content
MARKETS / NASDAQ / MTEX
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Mannatech Inc. MTEX

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$108.0M
▼ 8.3% YoY
$-15.2M
▼ 711.0% YoY
$-4.3M
▼ 319.8% YoY
In brief

What this company does

Mannatech, Incorporated develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products. It sells its products principally through network marketing distribution channels via its active associates and to its preferred customers. The company sells its products in three regions: the Americas (the United States, Canada and Mexico), Europe/the Middle East/Africa (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden and the United Kingdom), and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Thailand, Taiwan, Hong Kong, and China). The company employed 170 people as of December 31, 2025, compared with 189 a year earlier. As of December 31, 2025, the company had approximately 114,000 active associate and preferred customer positions held by individuals in its network associated with the purchase of its products and/or payment of associate fees within the last 12 months. The company operates as a single reportable segment across twenty-five markets. In China, the company operates through its subsidiary Meitai Daily Necessities & Health Products Co., Ltd., formed in 2016, which sells products under a cross-border e-commerce model in which consumers in China buy Mannatech products manufactured overseas via Meitai's website. Mannatech, Incorporated was incorporated and began operations in November 1993.

Written from the business description in MANNATECH INC's annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth
USD 108.0M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 108.0 · Net income -15.2
200M400M2007201020132016201920222025
Compound annual growth
−7.7%
−6.5%
−5.0%
−4.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −6.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−14 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -0.4% · Net -14.1%
2%4%6%-5%-10%2007201020132016201920222025
ROE
FY2025 · ROE -897.3%
-500%2007201020132016201920222025

Each USD of equity lost 897 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -4.3
4M8M-10M-20M2007201020132016201920222025
Net buybacks $M Dividends $M
FY2024 · Dividends 0.0 · Net buybacks 0.0
4M8MDividendsNet buybacks200720092011201320162018202020222024

Total assetsUSD 30.0M
EquityUSD -5.2M
CashUSD 6.2M
Gross debtUSD 2.8M
Net debtUSD -3.4M
Current ratio1.10×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.10.10.10.10.20.20.20.20.20.20.20.20.20.20.20.20.30.30.4
Operating income $B−0.00.0−0.0−0.00.00.00.0−0.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.00.0
EBITDA $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.00.0−0.0−0.00.0
Income tax $B0.00.00.00.0−0.0−0.00.00.00.0−0.00.00.0−0.00.00.0−0.0−0.0−0.00.0
Net income $B−0.00.0−0.0−0.00.00.00.0−0.0−0.0−0.00.00.00.0−0.0−0.0−0.0−0.0−0.00.0
Free cash flow $B−0.00.0−0.0−0.00.00.00.0−0.00.0−0.00.00.00.0−0.0−0.00.0−0.0−0.00.0
EPS, diluted $−8.001.32−1.20−2.354.712.771.35−1.53−0.66−0.222.142.401.18−0.52−7.80−4.01−6.56−0.480.25
Dividend / sh $··0.20············0.000.040.220.36
Payout %·0−33−34445436−79−76−1150···−0−0−6−46144
ROE %−897.326.1−18.2−23.339.123.512.5−11.9−4.5−1.516.723.714.5−6.6−65.9−25.8···
Shares out B0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 93 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image